



JUL 12 2007

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

TFA

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/585,651	Philip C Trackman	BU-112XX
INTERNATIONAL APPLICATION NO.		
PCT/US05/00631		
I.A. FILING DATE	PRIORITY DATE	
01/06/2005	01/13/2004	

207  
WEINGARTEN, SCHURGIN, GAGNEBIN & LEOVICI LLP  
TEN POST OFFICE SQUARE  
BOSTON, MA 02109

RECEIVED

BY:

MAY 23 2007

Date Mailed: 05/21/2007

WEINGARTEN, SCHURGIN,  
GAGNEBIN & LEOVICI LLP

CONFIRMATION NO. 5481

371 FORMALITIES LETTER



\*OC00000002396207\*

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5).

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

VONDA M WALLACE

---

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

---

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/585,651	PCT/US05/00631	BU-112XX

FORM PCT/DO/EO/922 (371 Formalities Notice)



Application No.: 10/585,651  
Deposited: July 7, 2006  
TC Art Unit: To Be Assigned  
Confirmation No.: 5481

**WEINGARTEN, SCHURGIN, GAGNEBIN & LEOVICI LLP**

Ten Post Office Square  
Boston, Massachusetts 02109  
Telephone: (617) 542-2290  
Telecopier: (617) 451-0313

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Date: July 10, 2007

Attorney  
Docket No.: BU-112XX

Sir:

**In re application of: Philip C. Trackman et al.**

**Entitled: USE OF THE PRO-PEPTIDE DOMAIN OF LYSYL OXIDASE AS A THERAPEUTIC AGENT**

Transmitted herewith is an **Amendment** in the above-identified application. The following checked items are applicable:

[ ] A Petition for Extension of Time for \_\_\_ month(s) is hereby made under §1.136(a); a check in the amount of \$\_\_\_ is enclosed per §1.17.

[X] In the event a Petition for Extension of Time is required by this paper and not otherwise provided, such Petition is hereby made and authorization is provided herewith to charge Deposit Account No. 23-0804 for the cost of such extension.

[ ] \_\_\_\_\_ is hereby appointed Associate Attorney by:

Registration No.:

\_\_\_\_\_  
Attorney of Record:  
Registration No.:

[X] Other: Sequence Submission Letter including: CRF Disk of Sequence Listing; paper copy of the Sequence Listing contained thereof; and copy of PTO Notice to Comply dated May 21, 2007.

CLAIMS AFTER AMENDMENT:	MINUS PRIOR PAID CLAIMS:	EQUALS PRESENT EXTRA CLAIMS:	RATE:	ADDITIONAL FEE:
Independent	2 - 3	= 0	x \$200.00 =	0
Total	15 - 20	= 0	x \$ 50.00 =	0
[ ] Multiple Dependent Claims (1st presentation)			+ \$360.00 =	0
<b>SUBTOTAL ADDITIONAL FEE</b>				0
Small Entity filing, divide by 2. Small Entity status must be asserted.				0
<b>TOTAL ADDITIONAL FEE</b>				0

[X] No additional fee. [ ] The fee has been calculated above; a check in the amount of \_\_\_\_\_ is enclosed.

[X] The Commissioner is hereby authorized to charge payment of any additional filing fees under §1.16 associated with this communication or credit any overpayment to Deposit Account No. 23-0804.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 10, 2007.

**SUBMIT IN TRIPPLICATE**  
HCH/aft/354189.1

*Holliday C. Heine*  
\_\_\_\_\_  
Attorney of Record: Holliday C. Heine, Ph.D.  
Registration No.: 34,346



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Philip C. Trackman et al.  
Application No. : 10/585,651  
Deposited : July 7, 2006  
Confirmation No. : 5481  
For : USE OF THE PRO-PEPTIDE DOMAIN OF LYSYL  
OXIDASE AS A THERAPEUTIC AGENT  
Examiner : To Be Assigned  
Attorney's Docket : BU-112XX

TC Art Unit: To Be Assigned

\*  
I hereby certify that this correspondence is being deposited with  
the United States Postal Service as first class mail in an  
envelope addressed to: Mail Stop Sequence, Commissioner for  
Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on  
July 10, 2007.

By Holliday C. Heine  
Holliday C. Heine, Ph.D.  
Registration No. 34,346  
Attorney for Applicant(s)

\* \*

SUBMISSION OF SEQUENCE LISTING

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the communication from the Examiner dated May 21, 2007 (copy enclosed), enclosed herewith is a Sequence Listing for the above-identified patent application including the following items:

a diskette containing a computer readable form (CRF) copy  
of the Sequence Listing;

Application No.: 10/585651  
Deposited: July 7, 2006  
TC Art Unit: To Be Assigned  
Confirmation No.: 5481

a paper copy of the Sequence Listing; and  
an amendment directing entry of the Sequence Listing into the application.

The undersigned Applicants' representative hereby states that that the information recorded in Computer Readable Form (CFR diskette) is identical to the written (on paper) Sequence Listing and that this information contains no new matter as required by 37 CFR 1.821(e) (f) (g) and 1.825(b) (d).

Respectfully submitted,

PHILIP C. TRACKMAN ET AL.

By Holliday C. Heine  
Holliday C. Heine, Ph.D.  
Registration No. 34,346  
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,  
GAGNEBIN & LEBOVICI LLP

Ten Post Office Square  
Boston, Massachusetts 02109  
Telephone: (617) 542-2290  
Telecopier: (617) 451-0313

HCH/aft/354176.1  
Enclosures